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Abstract
C-MPL EXPRESSION IN OSTEOCLAST PROGENITORS: A NOVEL ROLE FOR
THROMBOPOIETIN IN REGULATING OSTEOCLAST DEVELOPMENT. Calvin L Barnes, Yougen
Xi, Kimberly M Wilson, Mark C Horowitz, and Melissa A Kacena. Section of Bone Biology, Department
of Orthopaedic Surgery and Rehabilitation, Yale University, School of Medicine, New Haven, CT.

A new paradigm has evolved in which multiple regulatory interactions between the skeletal and
hematopoietic systems have been identified. Previous studies have demonstrated that megakaryocytes
(MK) play a dual role in skeletal homeostasis by stimulating osteoblast proliferation and simultaneously
inhibiting osteoclast (OC) development. Here we identify a novel regulatory pathway in which the main
MK growth factor, thrombopoietin (TPO), directly regulates osteoclastogenesis. To study the role of TPO
in OC development, spleen or bone marrow (BM) cells (2x106 cells/ml) or BM macrophages (BMM, 1x105
cells/ml) from C57BL/6 mice , as a source of OC precursors, were cultured with M-CSF (30 ng/ml) and
RANKL (50 ng/ml) to induce OC formation. TPO (0.1-1000 ng/ml) and/or primary MK (0-0.5%), derived
from C57BL/6 fetal livers, were titrated into these cultures and OC were identified as tartrate resistant acid
phosphatase positive (TRAP+) giant cells with >3 nuclei. There was a significant, up to 15-fold reduction
in OC formed when MK were added to all OC generating cultures, p < 0.001. Moreover, if OC generating
cultures did not contain MK or MK progenitors, TPO treatment significantly enhanced OC formation up to
six-fold, p < 0.01. This data demonstrates that MK are responsible for the inhibition of OC formation and
that in cultures containing MK or MK progenitors such as BM or spleen cells, that TPO acts indirectly to
inhibit OC formation by stimulating megakaryopoiesis, whereas in the absence of MK or MK progenitors
TPO directly enhances OC formation. This conclusion is further supported by Real-Time PCR data which
demonstrates that OC progenitors express c-mpl, the TPO receptor, albeit at low levels when compared to
expression of c-mpl on MK. Finally, we have begun to dissect the c-mpl signaling pathway in OC
progenitors. We have found that TPO induces tyrosine phosphorylation of several specific cellular proteins
in the JAK/STAT pathway. Thus, TPO acts in a somewhat paradoxical manner by inhibiting OC formation
through the stimulation of MK, while simultaneously playing a direct role in enhancing osteoclastogenesis.
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The Osteoclast
Bone is a dynamic tissue due to its intimate functional relationship to bone
marrow (BM). BM contains osteogenic, hematopoietic, and immune cells. Other cell
lineages are also present in BM and are supported by the stromal cell system. The close
juxtaposition of these cells makes BM the focus for many of the regulatory interactions
required for homeostatic development of bone. Changes in these regulatory interactions
may result in altered bone formation or resorption, providing clues as to how skeletal
homeostasis is maintained. Bone remodeling is a coupled process of bone resorption
followed by bone formation. This is a constant, balanced process and the interruption of
either bone resorption or formation leads to pathological conditions.
The mature, multi-nucleated osteoclast (OC) is the cell that resorbs bone. Early
studies, using electron microscopy demonstrated the ultrastructure of the actively
resorbing OC, and revealed distinguishing features. These consisted of large numbers of
lysosomes, vacuoles, and a specialized portion of its plasma membrane that lies adjacent
to bone actively being resorbed, now referred to as the “ruffled border” (1). This portion
of the plasma membrane is intricately folded with finger-like extensions into the
cytoplasm. Adjacent to the ruffled border is the sealing zone, which is directly apposed
to the bone and is composed of F- actin and punctuate protrusions of cytoplasm known as
podosomes that are devoid of organelles (2). The actin filaments and folds of the ruffled
border provide the OC with a controlled surface area where hydrogen and proteolytic
molecules can selectively dissolve bone. It is now known that when the OC is induced
to resorb bone, acidic vesicles containing proton pumps are recruited to the ruffled border
by the actin network (3-6). These proton pumps (H+ ATPases) secrete hydrogen ions
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and are accompanied by the concomitant release of chloride ions from chloride channels
(7). The net result of this process is creation of an acidic environment with hydrochloric
acid which demineralizes bone. Cathepsin K, a lysosomal protease, has been shown to
degrade the organic bone matrix following demineralization (8, 9).
OC are hematopoetic in origin. Some of the first evidence was discovered using
parabiosis techniques in which osteopetrotic mice and rats had their circulatory system
attached to their wild type, normal counterpart and osteoclastic activity was detected in
the osteopetrotic animals (10-12). Many recent studies demonstrate that OC are of the
monocyte/macrophage lineage, although the identity of the earliest OC precursor remains
elusive. This ongoing research is outside the scope of this paper. For a complete review,
consult Roodman (13). Currently there are 3 competing models of OC formation. The
first model states that the hematopoetic stem cell gives rise to granulocyte-macrophage
progenitor cell, CFU-GM, and that this cell produces OC. The second model proposes
that the hematopoetic stem cell produces CFU-GM, which in turn produces monocytes
and macrophages, of which some can be induced to form OC. The third model argues
that the hematopoetic stem cell produces CFU-GM and CFU-O, a distinct progenitor cell
which matures and fuses to form OC, and that CFU-GM does not directly produce OC
(13).
However, in spite of the controversy concerning the earliest stem cell, it has been
known for some time that in vitro maturation of macrophages into OC requires marrow
stromal cells or osteoblasts (OB) (14). It is now known that OB and marrow stromal
cells produce macrophage colony stimulating factor (M-CSF) and receptor for activation
of nuclear factor kappa B ligand (RANKL) and that these two factors are necessary for
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osteoclastogenesis (15-18). More recently, it was discovered that OB and stromal cells
also produce the soluble mediator osteoprotegrin (OPG) which acts as a decoy receptor
for RANKL, competing with RANK, thus inhibiting OC formation (18, 19). Fig. 1 is a
model illustrating the actions of RANKL, M-CSF, and OPG in OC development.

Figure 1. Model developed by Teitelbaum (42) depicting osteoclastogenesis and bone
resorption. OB and stromal cells express RANKL and M-CSF which interact with their
receptors, RANK and c-fms, respectively, on cells of the monocyte/macrophage lineage,
initiating OC development. OPG acts as a decoy by binding RANKL and inhibiting OC
formation. The mature OC attaches to the bone matrix and a ruffled membrane and
sealing zone are created. This small area of bone matrix contained within the sealing
zone is the microenvironment where bone resorption takes place. The acidic
environment generated by the OC mobilizes the mineral phase of bone and allows for
organic matrix degradation by cathepsin K.

It is becoming increasingly evident that within the stroma of the marrow, there
exist a complicated network of paracrine, cell-cell, and cell-matrix interactions that work
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in concert to regulate the production and activity of OC. Most notably, TNF-α and IL-1
have a direct stimulatory effect on OB and marrow stromal cells to produce RANKL and
M-CSF, thus promoting osteoclastogenesis (20). Moreover, TNF-α and IL-1 have been
shown to stimulate the production of adhesion molecules leading to increased cell-cell
interactions between bone stromal cells and hematopoietic cells (21). Also, IL-6 and IL11 have been shown to stimulate osteoclastic activity (22, 23). Several other factors are
known to inhibit osteoclastogenesis. In addition to OPG, these inhibitory molecules
include, but are not limited to: interleukin (IL)-4, IL-10, IL-12, IL-13, IL-18, interferon
gamma (IFN-γ), transforming growth factor beta (TGFβ), granulocyte-macrophagecolony stimulating factor (GM-CSF), OC inhibitory lectin (OCIL), calcitonin, amylin,
and calcitonin gene-related peptide (24-38). Therefore, it is likely that additional
undiscovered inhibitory cytokines exist.

The Megakaryocyte
Megakaryocytes (MK) arise from pluripotential, hematopoetic stem cells and pass
through a series of identifiable stages of differentiation, culminating in terminally
differentiated MK. The major function of MK is the formation of platelets. This occurs
by differentiated MK becoming ploidy through a process termed endomitosis.
Endomitosis consists of DNA replication and a mitotic event with sister chromatid
separation, but no cytokinesis (39). This leads to the formation of the demarcation
membrane system, an extensive system of membranes within the MK cytoplasm, which
gives rise to proplatelets. Proplatelets are the presumed structure between MK and
platelets that have been observed in vitro and in vivo (40). Proplatelets are long sinuous
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processes that extend from the MK and either fragment to form platelets or, alternatively,
attenuation points form pinching off newly formed functional platelets (41).
The molecular dissection of the MK differentiation pathway has been greatly
facilitated by the identification of transcription factors required for the cells successful
advance from stage to stage (Fig. 2). Loss of these specific factors precludes the cells
from continued maturation, and results in the accumulation of cells at the latest stage of
differentiation prior to the arrest. The selective loss of two different transcription factors,
GATA-1 and NF-E2, which were originally thought to be required exclusively for
erythroid lineage development, have now been shown to play a critical role in MK
differentiation. Knock-down mice in the case of GATA-1, and knock-out mice in the
case of NF-E2, exhibit a phenotype characterized by a marked megakaryocytosis and
thrombocytopenia (43, 44). The thrombocytopenia is a result of the maturational arrest
of MK differentiation in which GATA-1 halts differentiation at a stage between immature
and mature MK, where as NF-E2 arrests development at a later stage just prior to
terminal differentiation (Fig. 2).

Mk
Progenitor
Multipotential
Progenitor

FOG

FOG

Immature
Mk

GATA-1

Mature
Mk

Terminally
Mature
Mk

Platelets

NF-E2
maf

Figure 2. Schematic illustrating stages of MK differentiation and required transcription factors.
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Thrombopoietin, C-mpl, and Megakaryocyte Signal Transduction
The cytokine, thrombopoietin (TPO) is the primary mediator of primitive
megakaryocytic progenitor survival and proliferation, megakaryopoiesis, MK ploidy, and
maturation (45-52). Its’ receptor is the proto-oncogene c-mpl (53). The role of TPO and
its receptor c-mpl in thrombopoiesis was elucidated in the early to mid 1990s. The
pivotal experiments demonstrated that oligodeoxynucleotides antisense to c-mpl inhibited
in vitro megakaryocytopoiesis (54). The role of c-mpl as the TPO receptor was further
substantiated when it was shown that in murine models deficient in c-mpl, a
thrombocytopenic phenotype existed (55). The ligand to c-mpl, TPO, was then purified
and/or cloned by several research groups, clearly demonstrating its role as the primary
regulator of thrombopoiesis (50, 51).
TPO is a 332 amino acid polypeptide containing two recognizable domains. The
N-terminal region contains the receptor binding domain and is responsible for the
biological activity of TPO (46). The N-terminal region has marked homology to
erythropoietin (EPO) and its crystal structure has been identified as containing 4-αhelices arranged in an anti-parallel bundle fold (56, 57). This structural feature has been
demonstrated in many cytokines including granulocyte colony-stimulating factor (GCSF), GM-CSF, and growth hormone (GH) (58). The highly glycosylated, C-terminal
region is thought to be responsible for protein secretion and stability (59). TPO was
originally thought to be primarily produced by hepatocytes in the liver and convoluted
tubular cells in the kidney. However, in the last decade it has become increasingly clear
that TPO is also expressed in stromal cells within the BM (60-64). TPO has been
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measured in blood in response to thrombocytopenic states caused by both antibody
mediated and myelosuppressive techniques (65, 66).
C-mpl is a type I transmembrane protein belonging to the hematopoietic cytokine
receptor family (67). Similar to the common beta chain (βc) shared by IL-3, IL-5, and
GM-CSF, the extracytoplasmic domain of c-mpl consists of duplicate cytokine receptor
modules (CRM) (68). The cytoplasmic domain of c-mpl is highly conserved across
species. There is 86% homology, at the amino acid level, between mouse and human mpl
(69). The human c-mpl gene is composed of 12 exons (70). There are currently 4
identified splice variants of c-mpl. The predominant, full-length protein is referred to as
the P-form. In humans, the P-form consists of a transmembrane domain and 122
cytoplasmic residues. The K-form diverges from the P-form after the 9th cytoplasmic
amino acid and terminates within intron 10, this protein does not transduce a proliferative
signal and has no known biological activity; however, it is possible that mpl-K acts as a
dominant negative receptor by heterodimerizing with mpl-P following ligand binding
(71). The third splice variant, mpl-S, is a secreted form of mpl. Mpl-S results from
alternative splicing of exon 8 directly to exon 11. This eliminates the transmembrane
domain, the initial cytoplasmic residues, and the juxtamembrane WSXWS motif (70-72).
The 4th isoform, c-mpl-del, occurs from alternative splicing between exons 8 and 9 (lacks
72 bp), which results in the internalization of the receptor (73).
Two motifs in the cytoplasmic domain, box1 and box2, are conserved in the
hematopoietic cytokine receptor family, and are 100% homologous between mouse and
human mpl (69). Box1 appears to be required for signal transduction in all receptors
examined, while box2 is not necessarily required for proliferative signals (74-78).
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The signaling domain in c-mpl is 121 amino acids in mice and 122 amino acids in
humans. It is immediately downstream of the hydrophobic transmembrane domain which
is composed of 25 residues. While the c-mpl signaling domain is 91% homologous
between mouse and human, it does not share significant homology to other proteins (79).
The signal transduction of TPO when it binds to c-mpl is very complex and is the
subject of active research by several investigators. Evolution has seemingly fortified the
TPO/c-mpl signal transduction mechanism with redundancy to ensure a proliferative
signal will be transmitted (80). There is evidence that TPO signals proliferative events in
target cells through a JAK/STAT pathway. It was demonstrated that when TPO binds to
c-mpl, the receptor dimerizes, consequently tyrosine kinases, specifically JAK2 and
TYK2, activate each other by transphosphorylation (81). It was later shown that JAK2,
not TYK2 was required for mediated signaling (82). TPO is also known to induce
activation of STAT5 and STAT3 following JAK2 activation (83). STAT proteins, once
activated by tyrosine kinases, translocate to the nucleus and activate genes that signal
cellular growth and division such as cyclin D and p21.
TPO has also been shown to signal proliferation in cells with a JAK-STAT
deletion (84). This research group demonstrated that TPO mediated phosphorylation of
Shc, vav, mitogen-activated protein kinase (MAPK) and Raf-1, which then lead to
induction of c-fos and c-myc. Moreover, this group also demonstrated that wild-type and
mutant c-mpl receptors activated phosphatidylinositol (PI) 3-kinase when stimulated with
TPO and that TPO induced proliferation was suppressed in the presence of a PI 3-kinase
inhibitor. It is now evident that the MAPK signaling cascade, Shc, Ras signaling, as well
as PI 3-kinase, play some role in TPO signal transduction (85-90). More recently,
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microarray profiles demonstrated increased kinase activity in Fyn and Lyn in human
MKs after TPO stimulation, suggesting that Scr family kinases are also involved in TPO
signal transduction (91). Protein Kinase C (PKC) may play a role as well, but its
significance has not been tested (92, 93).

TPO, C-mpl and the Hematopoietic Stem Cell
There is a growing body of research demonstrating that TPO and c-mpl play some
role in the stimulation, proliferation, and development of HSC. When c-mpl was first
identified in 1993, it was shown to be expressed not only in MK and platelets, but in
purified CD34+ cells from BM and blood monocytes by RT-PCR (54). However, more
recently it was demonstrated by flow cytometry that 70% of murine HSC in BM are cmpl positive and that genetic elimination of c-mpl reduces the potency of HSC to
repopulate 7-fold (94). Dendritic cells, which develop from HSC, have also now been
shown to express c- mpl (95). Additionally, TPO has been reported to have a synergistic
effect with steel factor, an early HSC growth factor, and IL-3 to promote formation of
multilineage HSC colonies (96). Soluble c-mpl has also been shown to act in synergy
with steel factor to produce formation of multilineage colonies (97). Also, TPO has been
shown to act synergistically with granulocyte colony stimulating factor (G-CSF) to
promote neutrophil recovery in myelosuppressed mice (98).
Perhaps the most convincing evidence is from the study of c-mpl deficient mice.
It has been shown that mice with a c-mpl knockout have lower numbers of not only MK
progenitors and MK, but erythroid, granulocyte-macrophage, and multilineage precursor
cells as well (99). C-mpl mice now serve as a model system to study the human disease
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congenital amegakaryocytic thrombocytopenia (CAMT). CAMT is characterized by an
essential thrombocytopenia which develops into a pancytopenia / aplastic anemia later in
life. The disease has been shown to be caused by mutations in c-mpl, which further
suggests a role of TPO and its receptor in HSC survival and development (100).
This body of evidence demonstrates that c-mpl is not conserved strictly to MK
and is expressed on other cells at various stages of maturity in the hematopoietic lineage.
This research also suggests that TPO can act synergistically with other cytokines to
promote growth of granulocytes, macrophages, and erythroid progenitor cells.
Therefore, given that OC are also of the hematopoietic lineage, it is plausible that c-mpl
may be expressed on OC precursors and that TPO may play a direct role in
osteoclastogenesis.

The Megakaryocyte and Bone
Evidence for a role of MK in bone formation comes from data indicating that MK
express mRNA for, and secrete the bone matrix protein osteocalcin (39). The expression
of osteocalcin by BM MK and peripheral blood platelets is significant in that these are
the only known extra-osseous cells that secrete osteocalcin (39). In addition to
osteocalcin, MK or platelets also secrete other matrix proteins including osteonectin,
bone sialoprotein, and osteopontin (40, 41, 43, 44). More recently, bone morphogenetic
proteins -2, -4, and -6 have been immunolocalized in MK (101). These data suggest that
MK could, under the appropriate circumstances, contribute to bone formation by the
secretion of these proteins. On the other hand, MK have also been reported to stimulate
the differentiation of OB as defined by enhanced expression of procollagen (102).
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A limited amount of evidence also suggests a possible role for MK in OPG
mediated bone remodeling. In two investigations, immunohistochemical analysis showed
that MK stained positive for an OPG specific antibody (102, 103). Bord et al (102) also
showed that OPG expression increased in estradiol treated MK cultures as culture
duration increased, MK maturation also increased. In another study, MK expression of
OPG was documented using RT-PCR and immunolocalization techniques (104). Based
on immunostaining, these authors suggested that larger, more mature MK contained more
OPG. However, this latter study did not find demonstrable levels of OPG in human MK
conditioned medium (CM). While not determined experimentally, it was theorized that
the OPG, if secreted, binds significant amounts of the MK expressed RANKL (102, 105).
On the other hand, OPG was detected in CM from MK isolated from C57BL/6 and
GATA-1 mice (450±62 and 242±17 pg/ml, respectively) (106). Since MK from GATA-1
deficient mice are arrested at an immature stage of differentiation, this data lend further
support to the hypothesis that more mature MK contain higher quantities of OPG (107).
Moreover, the fact that MK appear to be a source of OPG implicates a potential role for
MK in regulating OPG levels and RANKL expression and implies that MK could be
involved in bone resorption and therefore bone remodeling.
Additional evidence for a role of MK in bone remodeling comes from studies of
mice deficient in GATA-1 and NF-E2, the previously described transcription factors
required for MK differentiation. Mice deficient in these transcription factors have a
phenotype characterized by increased numbers of immature MK, a concomitant drastic
reduction of platelets, and a striking increased bone mass (108-110). A marked 2-3-fold
increase in trabecular bone volume and bone formation indices were observed in these
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mice. A 20-150-fold increase in trabecular bone volume was measured for the entire
femoral medullary canal. In vivo OB number and bone formation parameters were
significantly elevated. When wild-type or mutant OB were cultured with MK from
GATA-1 or NF-E2 deficient mice, OB proliferation increased 3-6-fold by a mechanism
that required cell-to-cell contact. These observations demonstrated a novel interaction
between MK and OB which resulted in an increased bone mass, a here-to-fore,
unrecognized anabolic pathway in bone (110).

Cytokines Involved in Megakaryopoiesis and Osteoclastogenesis
Many of the pleiotropic cytokines that stimulate megakarypoiesis also play some
role in osteoclastogenesis. As Fig. 3 depicts, these cytokines include but probably are not
limited to IL-11, stem cell factor (SCF), leukemia inhibitory factor (LIF), IL-6, and GCSF (111). IL-11, in addition to its role in many stages of MK differentiation, is known
to stimulate macrophages (112, 113). Further IL-11 has been shown to upregulate
RANKL expression in cells of the OB lineage, which in turn can enhance OC formation
(114). Similarly, SCF, the ligand of c-kit, acts in the early stages of megakaryopoiesis
and is also known to enhance osteoclastogenesis (115, 116).
LIF has been documented as being involved with the differentiation of
multipotential progenitors into MK progenitors as well as the differentiation of MK
progenitors into immature MK (111). LIF has been implicated in modulating OC
differentiation by two separate mechanisms. First, LIF appears to upregulate RANKL
expression in cells of the OB lineage while simultaneously decreasing OPG expression
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(117). Additionally, LIF may upregulate c-fms expression in osteoclast precursors (118).
Both of these effects enhance osteoclastogenesis.
IL-6 promotes megkaryopoiesis, megakaryocyte differentiation, and raises
platelet levels in vivo (119-121). Like IL-11, IL-6 has been implicated in OC
differentiation through the upregulation of RANKL by cells of the OB lineage. In
addition to increasing RANKL expression, OPG expression is reduced with IL-6
stimulation, leading to enhanced osteoclastogenesis (122). G-CSF is important for the
normal differentiation of multipotential progenitors into MK progenitors (111). G-CSF is
also important in OC development. G-CSF facilitates the development of OC progenitors
from HSC and overexpression of G-CSF in vivo induces osteopenia as a result of
increased numbers of OC (123, 124).
Lastly, TPO, the main MK growth factor is critical for all stages of
megakaryopoiesis (47, 113, 125). It is unknown whether TPO has a direct effect on
osteoclastogenesis; however, given the wealth of data demonstrating an overlap of
cytokines involved in both megakaryopoiesis and osteoclastogenesis, it is plausible that
TPO could potentially directly affect osteoclastogenesis. The purpose of this current
research endeavor is to determine whether TPO directly affects osteoclastogenesis.

Thrombopoietin and Bone
There are only a few studies examining the role of TPO in skeletal homeostasis.
A myelofibrotic syndrome with osteosclerosis can be induced in mice by either repeated
injections with TPO or by infecting mice with a virus vector carrying the TPO gene (126-
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Figure 3. Pleiotropic cytokines involved in megakaryopoiesis and osteoclastogenesis.

128). The fibrotic disease was prominent in mice over expressing the factor at 9 months
of age. TGFβ-1 and platelet derived growth factor (PDGF), which are secreted by MK,
were increased 2-fold and 5-fold, respectively, in the platelet-poor plasma of the TPO
overexpressing mice as compared to controls (128). These data suggest that the MK
secrete increased amounts of TGFβ-1 and PDGF, which are responsible for the
myelofibrosis and osteosclerosis. This theory is also supported by recent work by
Vanucchi et al (129). These studies have shown that GATA-1 low mice and TPO
overexpressing mice both have a myelofibrotic phenotype and increased TGFβ-1 levels
in the extracellular fluid, therefore implicating the MK as the source of TGFβ-1 increase
that leads to myelofibrosis (129). Moreover, it has been shown that in mice with TGFβ-1
deficient BM, TPO overexpression does not induce myelofibrosis (130).
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Conversely, another study suggests that upregulation of OPG causes an
osteosclerotic phenotype in TPO overexpressing mice by inhibiting osteoclastogenesis
(131). These authors theorized that the OPG was derived from the stromal cells. In light
of the data showing that OPG is secreted by MK and the reports of OPG being expressed
or localized in MK, it is possible that MK could also be directly contributing to the OPG
levels described in the TPO overexpressing mice (102-104). Alternatively, like MK,
other non-mesenchymal/stromal cells could also be contributing to the increased OPG
levels.
A recent study by Kakumitsu et al (132) also supports a role of OPG and TGFβ-1
in the myelofibrotic, osteosclerotic phenotype in TPO overexpressing mice. Using
transgenic mice that continuously secrete TPO, this group demonstrated that the mice
develop anemia, myelofibrosis, and osteosclerosis. These mice had elevated numbers of
MK, with an accompanying significant increase in the plasma levels of TGFβ-1 and
OPG. Interestingly, these mice also demonstrated an increased number of peripheral
neutrophils in the blood, granulocytic immature cells, myeloid precursor cells, and
erythroid precursor cells in the BM despite the myelofibrosis and subsequent anemia,
further implicating a role for TPO in HSC survival and development.
Another investigation suggested that the mechanism of the increased bone
phenotype in TPO overexpressing mice was due to the inhibition of osteoclastogenesis
(133). In this study the effect of TPO on OC formation in vitro was examined. The data
showed that TPO reduced OC number in a dose-dependent manner. However like the
other previously mentioned studies, Wakikawa et al (133) reported that MK number and
maturation increased in these experiments.

21

The confounding factor in all of these studies is the presence of MK. Because
TPO stimulates MK proliferation, adding TPO to BM co-culture systems that contain
MK and/or MK progenitors, will by definition increase the number of MK in the culture
compared to cultures containing no TPO. Therefore, it is possible that the increased
number of MK is responsible for the inhibition of OC formation seen by Wakikawa et al
(133). Indeed, recent studies have shown that MK cultured in the absence of TPO, inhibit
OC formation in a dose-dependent manner (106). In addition, MK CM (TPO-free) also
inhibited OC formation in a dose-dependent manner (106). Therefore it appears that TPO
may play an indirect role in bone resorption by inhibiting OC formation by increasing
MK.
The role of TPO in bone homeostasis remains unclear due to the presence of MK
in these prior studies. The purpose of our research is to better characterize the
relationship between TPO and OC and to determine if a direct relationship exists
independently of MK.
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Hypothesis and Aims
From our review and analysis of the literature, there were three aspects which highlight
the purpose of this research. First, it was evident that c-mpl was not only expressed in
MK, but in other cells derived from HSC such as dendritic cells. Furthermore, it was
demonstrated that TPO acts synergistically with other cytokines to stimulate growth of
erythroid, granulocyte, and macrophage progenitors and therefore was not solely
restricted to cells of the MK lineage. Second, it was becoming increasingly evident that
several cytokines stimulate both megakaryopoiesis and osteoclastogenesis such as IL-11
and G-CSF. Third and last, there was substantial evidence supporting an indirect role for
TPO in inhibition of osteoclastogenesis by promoting megakaryopoiesis; however, a
more precise relationship between TPO and OC without the confounding effects of MK
has yet to be studied or reported in the literature. To this end, we hypothesized that OC
precursors express c-mpl, the TPO receptor, and that TPO directly affects OC
formation in vitro. The following specific aims test this hypothesis:

Specific Aim I.

To verify the ability of MK to decrease OC formation in vitro. OC

progenitors were cultured in the presence of M-CSF and RANKL to promote
osteoclastogenesis. Once OC were formed, cells were fixed, stained for tartrate resistant
acid phosphatase (TRAP), and TRAP+ multinucleated (>3) cells were counted. This
control population was then compared to a population of OC progenitors that had been
exposed to MK or MK CM to determine if a significant decrease in OC number had
occurred.
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Specific Aim II.

To test the effects of TPO to on OC formation in vitro in the

absence of MK and/or MK precursors. OC progenitors that did not contain MK or
MK precursors (Pax5-/- spleen cell line [SCL] and BMM) were cultured in the presence
of M-CSF and RANKL with or without TPO. Once OC were formed, cells were fixed,
stained for TRAP, and TRAP+ multinucleated (>3) cells were counted.

Specific Aim III. To characterize the expression of c-mpl in OC progenitors. Cmpl expression in OC progenitors was examined using Real-Time PCR (RT-PCR). RNA
was isolated from MK and OC progenitor cells. The RNA was converted to cDNA, and
subsequently purified prior to PCR amplification. MK served as a positive control for
expression of c-mpl. C57BL/6 BMM, RAW264.7, and Pax5-/-SCL were the OC
progenitor cells that were utilized.

Specific Aim IV. To begin dissecting the signal transduction pathway that occurs
when OC are stimulated with TPO. In Aim IV, we tested the hypothesis that TPO
induces receptor dimerization, tyrosine phosphorylation, and a series of signaling events
that results in the enhancement of OC development. Primary BMM derived from 6-8
week-old C57BL/6 mice or the Pax5-/- SCL OC progenitors were used. Cells were
serum starved overnight and then stimulated with 100 ng/ml of recombinant murine TPO
for 0, 1, 3, 5, 10, or 30 minutes. As a positive control, primary MK derived from the fetal
livers of E13.5-15.5 C57BL/6 mice or mpl-transfected, TPO dependent Ba/F3 cells were
serum starved and then stimulated with TPO for 0 or 10 minutes. Lysates were collected
and immunoblotted with antiphosphotyrosine antibodies (αP-Tyr).
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Materials and Methods

1**. Preparation of BM Cells: Tibiae and femurs were dissected from 6-10 week old
C57BL/6 mice, the epiphyses removed, and the marrow flushed with 2-3 mls of ice cold
α-MEM with 10% FCS (vol/vol) using a 27 gauge needle and syringe. A single cell
suspension was prepared and the cells were washed 2x prior to use.

2. Preparation of Whole Spleen Cells: Spleens from adult C57BL/6 mice were
dissected out and placed in a sterile culture dish containing PBS with 2% FCS (vol/vol).
The fibrous capsule was then broken, releasing spleen cells which were made into single
cell suspensions. Fibrous tissue was removed and cells were washed 2x.

3. Preparation of Fetal Liver cells: Although fetal livers and adult spleens are good
sources of MK, substantially more MK (at least 5x, data not shown) are obtained from
fetal liver preparations (MA. Kacena). Fetuses were dissected from pregnant mice at
E13.5-15.5. The livers were removed and single cell suspensions made by forcing cells
thru sequentially smaller gauge needles (18G, 20G, 23G). Cells were washed 2x with
DMEM + 10% FCS and then seeded (5 fetal livers/100 mm dish) in 100 ml culture
dishes, in DMEM + 10% FCS + 1% murine TPO (128). After 3-5 days, when the cells
become confluent, MK were obtained by separating them from the lymphocytes and
other cells using a one-step albumin gradient to obtain a 95% pure MK population (134).
The bottom layer was 3% albumin in PBS (Bovine Albumin, protease free, fatty acid
poor, Serologicals Proteins Inc.), the middle layer was 1.5% albumin in PBS, and the top
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layer contained the cells to be separated. All of the cells sedimented through the layers at
1g for approximately 40 minutes at room temperature. The MK fraction was collected
from the bottom of the vessel. The non-MK (NM) derived fraction was composed of the
remaining cells.

4. Preparation of MK CM: MK were isolated as described above, washed 2x, and
seeded into 6-well plates at a concentration of 1x106 cells/ml. They were cultured in αMEM supplemented with 10% FCS. After 72 hrs, the CM was centrifuged, sterile
filtered, aliquoted, and stored at -20ºC.

5*. Preparation of Bone Marrow Macrophages (BMM): BM cells were prepared as
above. 5x107 cells/ml were seeded into a 100 mm tissue culture dishes, in α-MEM
supplemented with 10% FCS and 20 ng/ml of M-CSF (R&D Systems). After 3 days in
culture, cells were lifted with trypsin, and were adjusted to a concentration of 100,000
cells/ml for OC generation as described below.

6*. Preparation of Pax5-/- SCL: Pax5-/- spleen cells (2.5x106 cells/ml) were prepared
as above, and were cultured in 100 mm tissue culture plates in α-MEM with 10% FCS
for 10 days. The nonadherent cells were washed away and the adherent cells were
released from the dish by treatment with EDTA/trypsin (0.032%). Pax5-/- SCL is a
purified monocyte/macrophage OC progenitor cell line developed by our laboratory,
which does not contain MK, lymphocytes, or other accessory cells. The Pax5-/-SCL was
chosen because OC develop from these cells in ~3 days, when cultured with M-CSF and
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RANKL to induce OC formation. The Pax5-/- SCL was transferred and fed weekly
(135).

7*. In Vitro OC-like Cell Formation Models: OC-like cells were generated by two
previously described methods (136, 137). First, co-cultures containing 2x106 spleen cells
or BM cells/ml and 20,000 primary calvarial OB/ml were grown in α-MEM
supplemented with 10% FCS and 10-8 M 1,25(OH)2D3. The media was changed every
other day for 6-8 days. Second, 2x106 spleen cells or BM cells/ml or 100,000 Pax5-/SCL or BMM were cultured in α-MEM supplemented with 10% FCS and 30 ng/ml of MCSF (R&D Systems) and 50 ng/ml RANKL (R&D Systems). Media was changed every
third day for 6-12 days (until OC formed). In each of the above models, once OC
formed, the cells were fixed with 2.5% glutaraldehyde in phosphate buffered saline for 30
minutes at room temperature, stained for TRAP using a kit from Sigma, and TRAP+,
multinucleated (>3) OC cells were counted. TPO was titrated (0-1000ng/ml) into
cultures.

8*. RNA Extraction and RT-PCR:

Cells were washed 2x with PBS. RNA was

isolated from the cells using a NucleoSpin II RNA Purification kit (BD Biosciences)
incorporating an on-column DNase treatment to remove contaminating genomic DNA.
For RT-PCR, cDNA was prepared from 5μg of total RNA using Sprint PowerScript
Reverse Transcriptase (BD Biosciences) and oligo(dT)12-18 primers. The cDNA was
purified using an Amicon YM30 filter device (Millipore). Quantitative RT-PCR was
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performed on a Cepheid Smart Cycler using Platinum Taq polymerase (Invitrogen) and
Sybr Green I (Molecular Probes) incorporation.
The quantitative comparison between samples was calculated using comparative
CT. The data was normalized by subtracting the difference of the threshold cycles (CT)
between the gene of interest (c-mpl) and the CT of the housekeeping gene glyceraldehyde
3-phosphate dehydrogenase (GAPDH). This value is defined as the ΔCT. To compare
the relative expression of c-mpl in two types of cells (e.g. primary C57BL/6 MK vs.
primary C57BL/6 BMM) the ΔΔCT must be calculated. ΔΔCT for this example is the
absolute value of the difference between the ΔCT for the MK and the BMM or |ΔCT MK ΔCT BMM|. The relative difference (fold increase or decrease) in expression is
calculated as 2ΔΔCT. The following were the sequences used for the c-mpl:
forward primer: 5’ TCACCTTGGTGACTGCTCTG
reverse primer: 5’ GGACTTAGGGCTGCAGTGTC
The following were the sequences used for GAPDH:
forward primer: 5’ CGTGGGGCTGCCCAGAACAT
reverse primer: 5’ TCTCCAGGCGGCACGTCAGA

9*. Cell Stimulation and Lysis: Seventy-five percent confluent cultures of C57BL/6
BMM and Pax5-/- SCL, C57BL/6 MK, or Ba/F3 cells were placed in reduced serum
media (0.5%) for 16-18 hours. The cells were stimulated with human recombinant TPO
(100 ng/ml) for 0, 1, 3, 5, 10, and 30 minutes. At the end of the incubation period, cells
were immediately rinsed with two changes of ice-cold PBS containing inhibitors (100
μM PMSF, 10 μg/ml leupeptin, 2 μg/ml aprotinin, 1 μg/ml pepstatin, 200 μM sodium
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orthovanadate). After aspirating the PBS/inhibitors, the cells were placed (adherent cells
were scraped) in the appropriate volume of lysis buffer containing 20 mM Tris, pH7.2,
150 mM NaCl, 1.0% Triton X-100, 1.0% sodium deoxycholate, 0.1% SDS, and 5.0 mM
EDTA. The following protease and phosphatase inhibitors were also added to the lysis
buffer: 1 mM PMSF, 10 μg/ml leupeptin, 10 μg/ml aprotinin, 1 μg/ml pepstatin, 1 mM
sodium orthovanadate, and 50 mM sodium fluoride. Lysates were centrifuged for 15
minutes a 12,000xg at 4°C and supernatants were collected. Protein concentration was
determined using a Micro BCA protein assay kit with BSA as the standard. Each sample
used for Western blotting was adjusted to contain equivalent amounts of protein.

10**. Western Blotting: Cell lysates (200-500 μg) were pre-cleaned with Protein ASepharose for 1 hour at 4°C. Protein A-Sepharose was removed and cell supernatants
were incubated in the appropriate antibody (e.g. αP-Tyr) for 2-16 hours at 4°C. The
antigen-antibody complexes were recovered during a 30-60 minute incubation using
rabbit anti-mouse immunoglobulin and protein A-Sepharose or protein A-Sepharose
alone. The immune complexes were washed 3-5 times with lysis buffer and the
immunoprecipitated proteins were eluted into SDS-PAGE sample buffer (3% SDS,
60mM Tris, pH 6.9, 2 mM EDTA, 4% glycerol) by heating the samples to 100°C for 5
minutes.

11*. Statistical Analysis: Statistical significance from controls was determined using
student’s t –test. For all figures, the data are presented as an average with the error bar
representing the standard deviation.
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* I conducted these experiments and generated data from them.
** I was trained in these procedures, but did not perform them regularly or generate data
from them.
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Results

MK Inhibit OC Development In Vitro
Spleen cells (2x106 cells/ml) from C57BL/6 mice, as a source of OC precursors,
were cultured with M-CSF (30 ng/ml) and RANKL (50 ng/ml) to induce OC formation.
It should be noted that similar data was obtained regardless of whether OC were
generated using spleen or BM cells as the source of OC precursors. Therefore, to avoid
redundancy we show only the data using spleen cells. C57BL/6 or GATA-1 deficient
MK were titrated into the culture wells and OC were identified as those cells that were
TRAP+ with >3 nuclei. Spleen cells (2x106 cells/ml) from C57BL/6 mice as a source of
OC precursors, demonstrated up to a 15-fold reduction in OC number when 5,000 or
10,000 MK were added to the spleen cell cultures, p < 0.001 (Fig. 4). This data also
shows that the MK from GATA-1 deficient mice are also able to inhibit OC formation in
vitro, but that the inhibition was significantly less pronounced, p < 0.04, than that seen
with equivalent numbers of C57BL/6 MK.
To rule out the possibility that the MK-induced OC inhibition was non-specific,
spleen cells treated with M-CSF and RANKL were cultured with MK, the non-MK (NM)
derived fraction (see preparation of fetal liver cells in Materials and Methods), or
C57BL/6 thymocytes as an unrelated cell type. A dose-dependent inhibition of OC
formation was again observed (Fig. 5). In contrast, at all concentrations tested, neither
thymocytes nor the non-MK cell fraction inhibited OC development. These data suggest
that the inhibition of OC formation was MK specific. Next, we confirmed that MK were
also able to inhibit OC formation in the co-culture model system. In these experiments
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C57BL/6 spleen cells (2x106 cells/ml) were cultured with freshly prepared C57BL/6
calvarial OB (20,000 cells/ml). Cultures were treated with 10-8 M 1,25(OH)2D3 to
enhance OC differentiation. C57BL/6 MK inhibited OC formation in a cell-number
dependent manner (data not shown).
Furthermore, inhibition of OC formation was also observed in the Pax5-/- SCL
model system. When just 2500 C57BL/6 MK (5%) were added to the SCL cultures,
there was a statistically significant, greater than 8-fold reduction in OC number recorded
when compared to control, p < 0.001. However, adding higher numbers of MK did not
further reduce OC number (Fig. 6).
Next, we generated MK CM and tested the ability of this CM to inhibit OC
formation. Here we cultured 1x106 C57BL/6 MK/ml, 1x106 GATA-1 deficient MK/ml
or 5x105 MEG-01 (a megakaryoblastic cell line) cells/ml for 3 days (pretested and shown
to have highest activity at day 3, data not shown) before collection. As Fig. 7 depicts,
C57BL/6 MK, GATA-1 deficient MK, and MEG-01 CM significantly inhibited OC
formation in a dose-dependent manner, p < 0.001. For C57BL/6 MK CM the ED50 was
approximately equal to 2% (vol:vol). These data indicate that a soluble factor(s) secreted
by either primary MK or a MK cell line was capable of inhibiting OC differentiation.
The data presented above demonstrate that MK cultured in the absence of TPO,
inhibit OC formation in a dose-dependent manner. Further, TPO-free MK CM also
inhibited OC formation in a dose-dependent manner. This data, performed in our
laboratory, serves as the preliminary results from which the following TPO experiments
were designed.
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Figure 4. Inhibition of OC formation by
MK after 9 days in culture. Both
C57BL/6 and GATA-1 deficient MK
markedly inhibited OC formation in vitro
(up to 15-fold reduction, * = p < 0.001),
although inhibition was reduced in
cultures containing GATA-1 deficient
MK (** = p < 0.04). Triplicate cultures
were tested within individual
experiments and experiments were
repeated 3 times.

Figure 5. Dose-dependent inhibition of
OC by C57BL/6 MK after 9 days in
culture. MK, non-MK (NM), or
thymocytes were titrated into spleen cell
cultures and were stimulated to induce
OC formation. MK inhibited OC in a
dose-dependent manner (* = p < 0.008).
NM and thymocytes did not inhibit OC
development at any of the concentrations
tested. Triplicate cultures were tested
within individual experiments and
experiments were repeated twice.

Figure 6. A greater than 8-fold reduction
in OC formation by C57BL/6 MK (BSAgradient separated on day 4) was seen
when the Pax5-/-SCL was used as a
source of OC precursors (* = p < 0.001).
Triplicate cultures were tested within
individual experiments and experiments
were repeated 3 times

Figure 7. CM concentration-dependent
inhibition of OC development (4 days in
culture) in Pax5-/-SCL culture model by
C57BL/6 MK CM, GATA-1 deficient MK
CM, and MEG-01 CM (* = p < 0.001).
Triplicate cultures were tested within
individual experiments and experiments
were repeated 3 times
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TPO Enhances OC Formation in Vitro in MK-Free Cultures
OC generated from Pax5-/- SCL cultured in the absence of MK demonstrated an
increase in cell number by 50-70% when stimulated with TPO, p < 0.04 (Fig. 7).
Recombinant human TPO was titrated into the OC-like cell formation models at day 0.
As shown in Fig. 8, with just 1 ng/ml of human recombinant TPO, OC number was 70%
higher than in cultures without TPO stimulation. Similarly, OC generated from C57BL/6
BMM in the absence of MK were increased in a dose-dependent manner when cultured
with TPO. A six-fold increase in OC number was observed when these cells were
cultured with 100 ng/ml of TPO, p < 0.01 (Fig. 9).
This data clearly demonstrates that TPO itself enhances OC formation in vitro.
However, if OC generating systems are used which contain MK and/or MK progenitors,
the effects of the MK inhibiting OC formation appears to outweigh the effects of TPO
enhancing OC formation, resulting in a net inhibition of OC formation.

C-mpl Expression in OC Progenitors
To determine whether OC progenitors express c-mpl, RT- PCR analysis was
completed. As described in the Materials and Methods section, the comparative CT
method was used to compare c-mpl expression in different types of cells. GAPDH
mRNA served as an internal control for the c-mpl mRNA. For each cell type used,
mRNA was extracted separately from 3 different cultures of cells, and the RT-PCR was
done in duplicate (the RAW264.7 OC progenitor cell line mRNA is based on only one
mRNA culture). All data are reported as the normalized minimum threshold cycle (ΔCT)

34

or the PCR amplification cycle at which the reporter dye fluorescence crossed the
selected threshold or baseline.

*
*

*

*

Figure 8. Stimulation of Pax5-/-SCL
OC precursors in the absence of MK
cells with TPO (1-1000 ng/ml)
enhances OC formation by 50-75%
(* = p < 0.04). Duplicate cultures were
tested within individual experiments
and experiments were repeated 3 times

Figure 9. Stimulation of C57BL/6 BMM in
the absence of MK with TPO (0.1-100
ng/ml) enhances OC formation by 6-fold
(100ng /ml TPO, * = p < 0.01). Duplicate
cultures were tested within individual
experiments and experiments were
repeated 3 times

As shown in Fig. 10, the ΔCT for c-mpl expression in primary C57BL/6 MK was
25.0±1.1. For OC progenitors, the ΔCT for c-mpl expression was 29.5±1.7 for primary
C57BL/6 BMM, 33.08±0.04 for RAW264.7 cells, and 33.2±2.2 for Pax5-/- SCL.
Although MK express significantly more c-mpl than do OC progenitors (2|ΔCT (MK)- ΔCT
(BMM)|

= 2|25.0-29.5| ≈ 22.6, a 22.6-fold increase), this data demonstrates that OC progenitors

express c-mpl (<35 CT is considered legitimate c-mpl expression). This conclusion is
further supported by our negative control, B9 cells (B cell). In B9 cell specimens, the
minimum threshold level was not exceeded with 40 cycles. This demonstrates the
specificity of c-mpl expression. Therefore, this expression data, in combination with the
functional data that shows that TPO enhances OC formation in vitro, implies that TPO is
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interacting with its receptor, c-mpl, on OC progenitors, and that this interaction begins a
cascade of signaling events which eventually results in enhanced OC formation.

Figure 10. Expression by RT-PCR of c-mpl
in C57BL/6 MK, C57BL/6 BMM, RAW264.7,
and Pax5-/-SCL. All OC progenitor cells
tested express c-mpl, albeit at lower
levels than primary MK. The data represent
the average ΔCT from duplicate testing of
three sets of mRNA (only one set of
RAW264.7 mRNA was analyzed).

TPO Induces Tyrosine Phosphorylation of Specific Cellular Proteins in OC
Progenitors
In MK and platelets, signal transduction by TPO has been shown to involve
tyrosine phosphorylation of several specific cellular proteins such as: JAK2, TYK2,
STAT3, STAT5, mpl, Shc, vav and SHIP. As shown in Fig. 11, TPO treatment of
C57BL/6 BMM induced tyrosine phosphorylation of proteins with the following apparent
mol wt: ~105-115, ~95, ~52, and ~46 kD. The majority of the proteins appeared to be
rapidly tyrosine phosphorylated within 1 minute after TPO stimulation. Phosphorylation
of the proteins reached maximal levels within 3-5 minutes after stimulation and
significantly diminished by 30 minutes. While immunoprecipitation of the specific
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cellular proteins has yet to be completed, these molecular weights are consistent with
signaling molecules known to by tyrosine phosphorylated when MK are stimulated with
TPO. Whether these same signaling molecules are tyrosine phosphorylated when OC
progenitors are stimulated with TPO is the subject of future research; however, this data
demonstrates a signaling cascade in OC progenitors when stimulated with TPO providing
more evidence for a direct interaction between TPO and OC.
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Figure 11. TPO induces tyrosine phosphorylation in
C57BL/6 BMM. BMM were treated with vehicle alone (0’)
or TPO (100 ng/ml) for the various time periods indicated.
Equal amounts of protein solubilized in lysis buffer (25
μg/time point) were separated on 7.5% SDS-PAGE,
transferred to nitrocellulose and probed with
antiphosphotyrosine antibodies. Bound antibody was
detected in the ECL reaction. The arrows on the right-hand
side indicate proteins that become tyrosine phosphorylated in
response to TPO.
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Discussion
In the last decade, a new paradigm has emerged in which MK have been shown to
play an important role in skeletal homeostasis. In brief, data demonstrate that MK may
act as an anabolic stimulator of bone formation by expressing/secreting bone related
proteins, or by directly enhancing OB proliferation and differentiation (39, 40, 41, 43, 44,
101, 102, 110, 138). Simultaneously, MK express and/or secrete several factors that are
known to be involved in osteoclastogenesis (37, 102, 103, 104, 105, 139-143). And,
recent studies demonstrate that MK inhibit OC formation in vitro (106). The net result is
that increases in MK can lead to increases in bone volume (110, 144).
One in vivo example of increases in MK leading to an increase in bone is TPO
overexpressing mice. Mice overexpressing TPO, the main MK growth factor, have an
approximate 4-fold increase in MK number and develop myelofibrosis with
osteosclerosis (126-128). These mice have significantly elevated levels of TGFβ-1,
PDGF, and OPG, all of which are known to be secreted by MK (106, 128, 131, 132, 143).
It was hypothesized that these elevated levels were responsible for the myelofibrosis and
osteosclerosis seen in TPO overexpressing mice.
To further dissect this hypothesis, Chagraoui and colleagues (130, 131) performed
several elegant experiments. First they showed that when irradiated wild-type recipient
mice were adoptively transferred with TGFβ-1-/- HSC that were infected with a
retrovirus encoding murine TPO protein, TPO overexpression did not induce the
myelofibrosis or osteosclerosis. However, when wild-type TPO-overexpressing HSC
were adoptively transferred, myelofibrosis and osteosclerosis was seen within 16-weeks
(130). Next, they performed mix and match adoptive transfer experiments with OPG.
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They demonstrated that all mice had elevated TGFβ-1 levels and that all mice developed
myelofibrosis, suggesting that TGFβ-1 and not OPG is critical for myelofibrosis to occur.
Next, they demonstrated that when wild-type recipient mice were adoptively transferred
with either wild-type or OPG-/- HSC that were infected with a retrovirus encoding
murine TPO protein, that serum OPG levels were elevated and osteosclerosis developed.
Interestingly, in OPG-/- recipient mice, an osteoporotic bone phenotype was observed
(131). This data suggests that OPG secreted by the BM stromal cells and OB in the wildtype recipient mice is responsible for the osteosclerosis seen in TPO overexpression.
In vitro studies by Wakikawa et al (133) also suggested that the osteosclerosis
seen in TPO overexpressing was due to inhibition of osteoclastogenesis. Their
experimental design utilized a co-culture model with BM cells and stromal cells which
inevitably contained MK and MK precursors. Their results demonstrated TPO mediated
inhibition of osteoclastogenesis in a dose-dependent manner. However, Wakikawa et al
(133) speculated the inhibitory effect of TPO on osteoclastogenesis in their co-culture
system to be due to increased thrombopoiesis and production of MK cytokines, namely
TGFβ-1 and PDGF. They found that antibodies to TGFβ-1 and PDGF, when introduced
into their model system, antagonized TPO induced inhibition of osteoclastogenesis.
Thus, it remains unclear if TPO has a direct role in osteoclastogenesis,
independent of MK. To elucidate whether TPO has a direct effect on osteoclastogenesis,
we did the following. First, we examined the relationship between MK and MK CM and
osteoclastogenesis. It is evident from our data that MK inhibit OC formation in vitro.
Spleen cells from C57BL/6 mice as a source of OC precursors demonstrated up to a 15fold reduction in OC number when 5,000 or 10,000 MK were added to the cell cultures

39

(Fig. 4). Furthermore, inhibition of OC formation was also observed in the Pax5-/- SCL
model system (Fig. 6). Additionally, MK CM was shown to inhibit OC formation in a
dose-dependent manner, suggesting that a soluble factor released by MK mediates OC
formation inhibition (Fig. 7).
Next, we studied the relationship between TPO and OC, independent of MK. Our
results clearly indicate that TPO exerts a direct effect on OC formation in vitro.
Experiments in which OC were generated in the absence of MK (Pax5-/- SCL)
demonstrated an increase in cell number by 50-70% when stimulated with TPO (Fig. 8).
Also, up to a six-fold increase in OC number was observed after culturing C57BL/6
BMM cells (no MK) with TPO (Fig. 9). Interestingly, the response of C57BL/6 BMM
cells to TPO was greater than that of the Pax5-/- SCL cells. This data suggests that
primary cells such as C57BL/6 BMM are more responsive to TPO stimulation than cells
lines such as Pax5-/- SCL. Moreover, since primary cells more closely model
physiological response, these results further substantiate a direct role of TPO in OC
formation. The argument can be made that primary cells inevitably contain some degree
of contaminating cells and that the results could be spurious. However, all non-adherent
cell were removed from cultures, so contaminating cells were adherent. Furthermore, as
cells were induced to become OC, and since only OC were assessed in this assay by
TRAP staining, only BMM or other OC precursors were responding to TPO stimulation.
It is evident from this data that the presence of MK or MK precursors would
confound any attempt to elucidate a possible direct effect between TPO and
osteoclastogenesis. Wakikawa et al (133) observed that TPO inhibited in vitro
osteoclastogenesis in a dose-dependent manner. However, their co-culture model
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contained MK and MK precursors. We confirmed the dose-dependent osteoclastogenesis
that Wakikawa et al (133) observed by introducing increasing numbers of MK into OC
progenitor cell cultures (Fig. 5). This suggests that Wakikawa et al (133) observed an
indirect inhibitory effect of TPO on osteoclastogenesis due to increased
megakaryopoiesis.
Since the MK mediated inhibition of OC formation dominates the direct effect of
promoting osteoclastogenesis by TPO, the implications of this direct relationship between
TPO and OC progenitors remains unclear. As detailed in the literature review, at least
70% of HSC are c-mpl positive, and mature, hematopoietic non MK cells such as
dendritic cells express the TPO receptor (94, 95). Moreover, there is a growing body of
research that suggests synergistic relationships between TPO and other growth cytokines
such as G-CSF and IL-3 are essential to stem cell survival and proliferation (96, 98).
Carver-Moore et al (99) have shown that mice with a c-mpl knockout have lower
numbers of not only MK progenitors and MKs, but erythroid, granulocyte-macrophage,
and multilineage precursor cells as well. It is well established that OC are hematopoietic
in origin. Moreover, our data demonstrate that OC progenitors express c-mpl, albeit at
low levels when compared to MK (Fig. 10). Specifically, we found that the level of
expression of c-mpl on OC progenitors is approximately 22.6-fold less than that found in
MK. This suggests that MK most likely bind the majority of TPO, and hence cause a net
inhibition of osteoclastogenesis when stimulated with TPO, an indirect effect. However,
our data suggests that there is also a concomitant, direct, TPO-mediated signal to OC
progenitors that promotes osteoclastogenesis. Given the previously described research
pointing to a crucial role for c-mpl in stem cell survival for multi-lineages of
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hematopoietic cells, the direct stimulation of OC formation by TPO may be necessary for
the survival and proliferation of this specific HSC population that produces OC.
Our preliminary data suggests not only that c-mpl is expressed in OC progenitors,
but more importantly, it is functional. We observed rapid onset of tyrosine
phosphorylation by Western blotting with 1 min with maximal activity at 3-5 min,
tapering off by 30 minutes (Fig. 11). Drachman et al (145) demonstrated that TPO
binding to c-mpl induces tyrosine phosphorylation evident within 1 minute, generally
peaking between 5-10 minutes, and decreasing by 60 minutes. In their experiments,
BaF3 cells expressing the c-mpl receptor had a dramatic increase in tyrosine
phosphorylation in response to TPO. The most prominent phosphotyrosine proteins
migrated at 52 kD, 95 kD, with several bands between 115 and 125 kD, and 140 kD; less
intense bands were seen at 45, 65-75, and 110 kD. Our results of tyrosine
phosphorylation occurring at ~105-115, ~95, ~52, and ~46 kD show a great deal of
overlap. Drachman et al (145) identified through immunoprecipitation, phosphorylated
Shc at 52 kD and c-mpl dimer at 95 kD doublet as well as JAK2 at 125 kD. Although
immunoprecipitation assays are needed to identify the proteins being phosphorylated in
our study, we did observe tyrosine phosphorylation at 52 kD and 95 kD suggesting that
most likely, TPO/c-mpl signaling is well conserved among cell types. But it is plausible
that other proteins could migrate at these weights. More importantly, this data clearly
demonstrates that the c-mpl receptor on OC precursors is functional and that TPO
stimulation initiates a time-dependent tyrosine phosphorylation cascade in OC precursors,
a cell signaling event. This further supports a direct role for TPO in osteoclastogenesis.
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We have demonstrated that TPO as well as MK both have direct and opposing
effects on OC formation. We propose the following model (Fig. 12): TPO is secreted by
cells of the OB lineage. Secreted TPO can bind to either cells of the MK lineage or cells
of the OC lineage. When TPO binds to cells of the MK lineage, MK proliferation and
differentiation occurs. Increases in MK number result in increases in OB number by a
direct cell-to-cell mechanism. Increases in MK number also results in an increase in the
secretion of soluble mediator(s) that inhibit OC formation. Simultaneously, TPO can
bind c-mpl on OC progenitors, which results in an increase in OC formation and/or
survival of HSC precursors of OC.
In closing, our research has demonstrated a novel role for TPO as a stimulatory
cytokine promoting osteoclastogenesis. Moreover, we have also shown that not only is cmpl expressed on OC progenitor cells, but is also a functional receptor. It has become
evident through the literature that MK play a role in skeletal homeostasis. However, until
now, the role of TPO has never been studied independently of MK. Our research is the
first to examine the relationship between TPO and OC independently of MK. We have
shown that TPO plays a direct role in skeletal homeostasis by enhancing OC
development. Future research will be aimed at dissecting the TPO signaling pathways
in OC, as well as functional bone resoprtion by OC stimulated with TPO. Such research
will provide even more insight and knowledge about the relationship between TPO and
OC, in the hopes of continuing to reveal the mechanisms underlying skeletal homeostasis
and the roles of TPO and MK in bone remodeling.
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Figure 12. Model of how TPO both directly
and indirectly regulates skeletal
homeostasis. TPO that is secreted by
OB/bone marrow stromal cells (BMSC) can
bind to either MK or OC progenitors. Cmpl signaling in MK progenitors results in
enhanced MK proliferation. MK then
interact with OB/BMSC via direct cell-tocell contact which in turn upregulates
OB/BMSC proliferation (positive feedback
loop). At the same time, MK secrete a
factor that inhibits OC formation. On the
other hand, TPO can bind c-mpl on OC
progenitors, which results in increased OC
formation.
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